INFORMATION FOR
News
Researchers across Yale School of Medicine published a new study in The Journal of Clinical Investigation that sheds light on how SGLT2 inhibitors work to protect the heart.
A team has uncovered a new process that potentially delays the development of liver fibrosis in patients with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD).
Arya Mani MD, and colleagues have discovered a therapeutic target for the treatment of nonalcoholic fatty liver disease and liver insulin resistance in type 2 diabetes.
59 Staff in Department Celebrate Service Milestones
Discoveries & Impact (September 2020)